Lack of successful therapeutic development to date. |
The remarkable diversity of risk factors for AD. |
The high prevalence of AD in the elderly. |
The mechanism(s) by which ApoE4 increases risk for AD. |
The physiological role(s) of Aβ peptides. |
The anatomic pattern of spread of AD pathology. |
The association of plastic brain regions with AD pathology. |
Why some people, and transgenic mice, collect large amounts of Aβ peptide without displaying symptoms of AD. |
The relationship between Aβ and tau pathology. |
The α7 paradox (i.e. α7 has been reported to mediate both enhancement and inhibition of neurodegeneration) (Dziewczapolski et al, 2009; O'Neill et al, 2002) |